Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Day One Biopharmaceuticals (DAWN) Change in Intangibles (2024 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Change in Intangibles for 2 consecutive years, with $3.5 million as the latest value for Q1 2025.

For Q1 2025, Change in Intangibles changed N/A year-over-year to $3.5 million; the TTM value through Dec 2025 reached $3.5 million, down 79.53%, while the annual FY2025 figure was $3.5 million, 79.53% down from the prior year.
Change in Intangibles was $3.5 million for Q1 2025 at Day One Biopharmaceuticals, down from $17.1 million in the prior quarter.
The five-year high for Change in Intangibles was $17.1 million in Q2 2024, with the low at $3.5 million in Q1 2025.